Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid mesotherapy versus triple-combination topical therapy for melasma
IRCT20210823052264N1Phase 3Completed
- Sponsor
- PNS Shifa
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tranexamic acid, hydroquinone, fluocinolone and tretinoin in melasma (2 arms), sponsored by PNS Shifa. Primary endpoint: Degree of melasma treatment. Started Jul 2021; status: completed.
02
Drugs
tranexamic acidhydroquinonefluocinolonetretinoin
03
Conditions
melasma
Beyond the preview
Go deeper on IRCT20210823052264N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210823052264N1.